Popular cold, flu medicine could be pulled from market for ineffectiveness


Full story

Cold and flu season is here and many may be reaching for medicine for relief but a popular remedy may soon no longer be available. The Food and Drug Administration said it’s planning to pull a widely used ingredient from shelves.

It’s called oral phenylephrine and is used in cough and cold medicines from household names like Advil, NyQuil, Sudafed, Robitussin, Tylenol and Theraflu.

QR code for SAN app download

Download the SAN app today to stay up-to-date with Unbiased. Straight Facts™.

Point phone camera here

More than a year ago, the FDA’s advisers voted against continuing to use the ingredient over concerns about the data used to support its approval and new data that shows it might not be effective. After that vote, CVS said it would pull any products on its shelves that only contained the product.

A 2022 study from the University of Florida found phenylephrine basically only had a placebo effect when swallowed. The latest FDA data, published this week, shows less than 1% of phenylephrine is absorbed into the body when taken orally through a pill or cough syrup.

Researches found it’s more effective in certain forms, like a nasal spray, because more can get into the bloodstream.

The public gets to weigh-in on the decision until May 7, then the FDA will decide whether to revoke its status as “generally recognized as safe and effective.”

Tags: , , , ,

SAN provides
Unbiased. Straight Facts.

Don't just take our word for it.


Certified balanced reporting

According to media bias experts at AllSides

AllSides Certified Balanced May 2025

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more

SAN provides
Unbiased. Straight Facts.

Don't just take our word for it.


Certified balanced reporting

According to media bias experts at AllSides

AllSides Certified Balanced May 2025

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more

Media landscape

Click on bars to see headlines

80 total sources

Key points from the Center

No summary available because of a lack of coverage.

Report an issue with this summary

Key points from the Right

No summary available because of a lack of coverage.

Report an issue with this summary

Other (sources without bias rating):

Powered by Ground News™